|
Market Cap (17-May) $8,414,961,152 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (5-May) 16,072,273 (4.76%) (53rd) |
|
52w High $31.97 |
52w Low $14.42 |
P/E 57.80 |
EPS 0.15 |
TLX released this announcement to the ASX on 31 January 2022, 8:29. The announcement is not marked as price sensitive, and is 4 page(s) in length and 225.82kb in size.
You can view all announcements from TLX and see how they appear on a price chart on the announcements page.
At the date of this announcement, TLX was 0.641% short sold according to ASIC data. It was ranked the 245th most shorted stock on the ASX. It is now ranked as the 53rd most shorted stock on the ASX with 4.757% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from TLX | |
|---|---|
| Cleansing Notice | 28 June 2023, 8:23 |
| Application for quotation of securities - TLX | 28 June 2023, 8:23 |
| Proposed issue of securities - TLX | 21 June 2023, 18:12 |
| App 3Y Change of Directors Interest Notice - C Behrenbruch | 31 January 2022, 8:29 |
| Cleansing Notice under S708A(5)(e) Corporations Act 2001 | 28 January 2022, 10:00 |
| Application for quotation of securities - TLX | 27 January 2022, 12:01 |
| 1st Patient Dosed ProstACT Prostate Cancer Therapy Program | 27 January 2022, 8:22 |
You must be logged in to post a reply.
Telix Pharmaceuticals 